HR Execs on the Move

Emergent BioSolutions

www.emergentbiosolutions.com

 
Emergent BioSolutions is a global life sciences company dedicated to one simple mission—to protect and enhance life. We develop, manufacture, and deliver a portfolio of medical countermeasures for biological and chemical threats as well as emerging infectious diseases.
  • Number of Employees: 1K-5K
  • Annual Revenue: $100-250 Million

Executives

Name Title Contact Details
Eric de los Santos
Assistant General Counsel, Labor and Profile
Greg Terry
North American Director of Sales and Business Development Profile
David Maust
Director Supply Chain Profile
Shannon Beaty
Director of Vaccines R&D Profile
Lo Vang
Senior Director, Translational R&D Profile

Jobs

VP, Chief Information Security Officer

Emergent BioSolutions Remote
Details here:
https://careers.emergentbiosolutions.com/job/Gaithersburg-Vice-President%2C-Chief-Information-Security-Officer-Remote-MD-20879/1200080000/?feedId=306800&utm_source=Indeed&utm_campaign=EmergentBio_Indeed&jobPipeline=Indeed

Similar Companies

Palleon Pharmaceuticals

Palleon is targeting glycan-sensing checkpoints to unleash both the innate and adaptive immune responses to cancer.

Paragon Bioservices

Paragon Bioservices is an industry-leading, private-equity backed contract development and manufacturing organization (CDMO) whose focus is the development and manufacturing of cutting-edge biopharmaceuticals. Paragon`s aim is to build strong client partnerships with the world`s best biotech and pharma companies, focusing on transformative technologies, including gene therapies (AAV), next-generation vaccines, oncology immunotherapies (oncolytic viruses and CAR-T cell therapies), therapeutic protein, and other complex biologics.

Outlook Therapeutics

Oncobiologics, Inc. has changed its name to Outlook Therapeutics, Inc. Outlook Therapeutics is a clinical-stage biopharmaceutical company focused on developing its lead clinical program, ONS-5010, a proprietary ophthalmic bevacizumab product candidate for the treatment of wet age related macular degeneration (wet AMD). ONS-5010 is currently in its first clinical trial, which is being conducted outside of the U.S. and is designed to serve as the first of two adequate and well controlled studies for wet AMD.

Pionyr Immunotherapeutics

Pionyr Immuntherapeutics (formerly Precision Immune Inc.) is developing cancer immunotherapies that target the tumor microenvironment to enhance the body`s antitumor immunity. The company is exploiting novel target discovery and antibody generation platform technologies to create the next generation of immuno-oncology therapeutics. The company`s approach, Myeloid Tuning™, is designed to enhance the immune system`s anti-tumor response by altering the cellular infiltrate of the tumor microenvironment with high specificity.

22nd Century Fox

22nd Century is a plant biotechnology company whose proprietary technology allows for the levels of nicotine and other nicotinic alkaloids (e.g., nornicotine, anatabine and anabasine) in the tobacco plant to be decreased or increased through genetic engineering and plant breeding. 22nd Century owns or is the exclusive licensee of 116 issued patents in 78 countries plus an additional 42 pending patent applications. Goodrich Tobacco Company, LLC and Hercules Pharmaceuticals, LLC are wholly-owned subsidiaries of 22nd Century. Goodrich Tobacco is focused on commercial tobacco products and potentially less harmful cigarettes. Hercules Pharmaceuticals is focused on X-22, a prescription smoking cessation aid in development.